Despite broader group performance facing headwinds this year, Qisda Corporation’s medical business has maintained steady growth. Fourth-quarter results for the medical segment are expected to show year-on-year (YoY) growth, setting the stage for the division's revenue to exceed the NT$30 billion milestone in 2025.
Read more
